Ipilimumab-related hypophysitis may precede severe CNS immune attack
نویسندگان
چکیده
منابع مشابه
[Ipilimumab, a cause of autoimmune hypophysitis].
Hypophysitis represents a heterogeneous group of inflammatory lesions affecting the pituitary gland with a complex pathogenesis and is insufficiently characterized. The different types belong to the group of non-hormone secreting sellar masses, with which they share clinical, and sometimes also radiographic, presentation. These similarities make differential diagnosis difficult in the absence o...
متن کاملIpilimumab-induced hypophysitis: MR imaging findings.
Ipilimumab is a promising new immunotherapeutic antineoplastic agent with clinical activity in the treatment of metastatic melanoma and renal cell carcinoma. With advances in immunotherapy, however, a host of new side effects related to the mechanism of action of these drugs has appeared. At our institution, 3 patients presented with hypophysitis, which was attributed to an autoimmune process b...
متن کاملIpilimumab-induced autoimmune hypophysitis: a differential for sellar mass lesions
UNLABELLED Autoimmune hypophysitis (AH) has been previously described in a typical demographic population, primarily women in the reproductive age group and perinatal period. The era of immune modulation using anti-cytotoxic T-lymphocyte-associated antigen 4 biological therapy (ipilimumab) against advanced cancers like metastatic melanomas has now resulted in a new form of hypophysitis being in...
متن کاملManaging immune-related adverse events to ipilimumab: a nurse's guide.
Ipilimumab is a U.S. Food and Drug Administration-approved novel T-cell potentiator that improves survival in metastatic melanoma. Ipilimumab blocks cytotoxic T-lymphocyte antigen-4, a negative regulator of the immune response, thus promoting T-cell activation and prolonging a patient's antitumor response. However, that action may produce a mechanism-related spectrum of immune-related adverse e...
متن کاملImmune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy
CTLA-4: cytotoxic T-lymphocyteeassociated antigen 4 irAEs: immune-related adverse events PD-1: programmed deathe
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2016
ISSN: 0923-7534
DOI: 10.1093/annonc/mdw255